1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs

  • May 2015
  • 126 pages
  • GBI Research
Report ID: 3007698

Summary

Table of Contents

Search Inside

Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs", which provides in-depth analysis of Rheumatoid Arthritis (RA) market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2014, along with market forecast until 2021. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the RA market in the APAC region amounted to an estimated $5.6 billion in 2014 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.3% to reach $6.9 billion by 2021. The key drivers for growth in the APAC market include: the increasing prevalent population and the anticipated market launch of promising pipeline candidates. The late-stage pipeline which has a potential to stimulate growth during the forecast period include interleukin (IL)-6 inhibitors Sanofi/Regeneron’s sarilumab, Johnson & Johnson/GlaxoSmithKline’s [J&J/GSK’s] sirukumab, small molecules (four janus kinase [JAK] inhibitors: Eli Lilly/Incyte’s baricitinib, Loss of patent exclusitivity of major second-line biologic anti-TNF during such as Enbrel, Remicade and Humira by the end of the forecast period is the major barrier for growth in the RA market size in the APAC markets. Preference for less expensive alternatives to branded medicines, such as biosimilars and other alternate therapies is another major barrier in cost-conscious APAC markets, India and China.

Scope

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for RA. It covers and includes -
- A brief introduction to RA, including the disease’s pathophysiology, risk factors, diagnosis and an overview of pharmacotherapy and treatment algorithms.
- In-depth analysis of the drug combinations used in the treatment of RA, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy
- A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration
- Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action
- Multi-scenario forecast market data to 2021, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets
- Discussion of the drivers and barriers for market growth
- In-depth analysis of licensing and co-development deals involving drugs indicated in RA, including an outline of the key deals

Reasons to buy

Primarily, the report will allow clients to gain a strong understanding of RA, helping to identify and clarify market opportunities and the competitive environment. It will also allow you to -
- Understand the RA pipeline and the key trends in the current product development landscape
- Observe detailed profiles for the promising pipeline products, including revenue forecasts, and gain an insight into how they are likely to compete in the market, and what their main competitors will be
- Follow the trends in RA clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs for RA therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates
- Observe the potential growth patterns expected for the RA market over the forecast period, and identify which countries are expected to make the biggest contribution to this growth.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Axial spondyloarthritis (axSpA) Market and Forecast Analyst to 2024

  • $ 22000
  • Industry report
  • April 2017
  • by Datamonitor Healthcare

Introduction Axial spondyloarthritis (axSpA) is a chronic, systemic, inflammatory rheumatic disease that predominantly affects the spine and sacroiliac (SI) joints, leading to chronic back pain. The chronic ...

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025 Summary Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death among gynecological ...

PharmaPoint: Chronic Obstructive Pulmonary Disease - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

PharmaPoint: Chronic Obstructive Pulmonary Disease - Global Drug Forecast and Market Analysis to 2025 Summary COPD is a progressive lung disease characterized by an abnormal inflammatory response and airflow ...

Nash: Kol Insight [2017]

June 2017 $ 9015

Car-t Disease Outlook [2017]

June 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in the US

  • August 2017
    9 pages
  • Anti-Infective  

  • United States  

View report >

Anti-Infective and Therapy Market in Brazil

  • August 2017
    11 pages
  • Anti-Infective  

    Therapy  

    Vaccine  

View report >

Anti-Infective Market in the UK

  • August 2017
    21 pages
  • Anti-Infective  

    Antibiotic Resi...  

  • United Kingdom  

    Europe  

View report >

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.